Pharming announces positive topline data in pediatric clinical trial of leniolisib
Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the previously reported randomized controlled trial in adolescent and …